The evidence base for longevity medicine, synthesized.
A working reference for the small number of physicians treating at the frontier of geroscience — graded, dated, and citation-ready, without the supplement-stack copy.
Geroevidence indexes every trial, registry, cohort, and meta-analysis on the longevity pharmacopeia — rapamycin, metformin, GLP-1 receptor agonists, SGLT2 inhibitors, acarbose, senolytics, NMN, and the rest — and grades each on a four-tier evidence ladder running from mechanism to hard outcomes.
Each intervention has a single, dated profile. Hazard ratios are pooled with confidence intervals. New papers enter the feed within twenty-four hours of indexing, but never the profile itself until a clinician reviews them. No claim appears without a citation; no citation appears without a grade.
The platform was built for clinicians and researchers who want the evidence without the editorial spin.